Published in PLoS One on February 16, 2012
Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One (2013) 1.36
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 1.07
Metabolic profiling of Alzheimer's disease brains. Sci Rep (2013) 0.94
Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta (2013) 0.92
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86
Cerebrospinal fluid cortisol and progesterone profiles and outcomes prognostication after severe traumatic brain injury. J Neurotrauma (2014) 0.86
Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. J Neurol (2014) 0.81
1H NMR Analysis of Cerebrospinal Fluid from Alzheimer's Disease Patients: An Example of a Possible Misinterpretation Due to Non-Adjustment of pH. Metabolites (2014) 0.79
Aspartic acid in the hippocampus: a biomarker for postoperative cognitive dysfunction. Neural Regen Res (2014) 0.78
A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy. PLoS One (2016) 0.78
Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder. Biochim Biophys Acta (2016) 0.78
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. Alzheimers Res Ther (2015) 0.77
The impact of stress and glucocorticoids on memory. Clujul Med (2014) 0.76
Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty. Mol Med Rep (2016) 0.75
Investigation of the Material Basis Underlying the Correlation between Presbycusis and Kidney Deficiency in Traditional Chinese Medicine via GC/MS Metabolomics. Evid Based Complement Alternat Med (2013) 0.75
Amino Acid Catabolism in Alzheimer's Disease Brain: Friend or Foe? Oxid Med Cell Longev (2017) 0.75
Quantitative in vivo neurochemical profiling in humans: where are we now? Int J Epidemiol (2016) 0.75
Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. Alzheimers Dement (Amst) (2017) 0.75
Synaptic Membrane Synthesis in Rats Depends on Dietary Sufficiency of Vitamin C, Vitamin E, and Selenium: Relevance for Alzheimer's Disease. J Alzheimers Dis (2017) 0.75
Metabolic status of CSF distinguishes rats with tauopathy from controls. Alzheimers Res Ther (2017) 0.75
Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia. Dement Geriatr Cogn Dis Extra (2017) 0.75
Metabolomics and cognition in African American adults in midlife: the atherosclerosis risk in communities study. Transl Psychiatry (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 6.84
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Penalized logistic regression for detecting gene interactions. Biostatistics (2007) 5.53
Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant J (2000) 4.64
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Alzheimer disease. JAMA (2002) 1.95
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One (2010) 1.92
Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology (1982) 1.64
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis (2009) 1.49
Cortisol and Alzheimer's disease, I: Basal studies. Am J Psychiatry (1986) 1.20
Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics (2006) 1.19
Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) (2011) 1.15
The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett (2007) 1.12
Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry (1997) 1.09
Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res (1990) 1.08
Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract (2009) 1.08
Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging (2006) 0.98
Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. Eur Arch Psychiatry Clin Neurosci (2008) 0.92
Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging (1988) 0.90
Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods (2008) 0.89
Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev (2010) 0.87
Alzheimer's disease and total plasma aminothiols. Biol Psychiatry (2003) 0.87
CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2007) 0.85
Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Rev Proteomics (2010) 0.84
Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett (1994) 0.84
Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J Neural Transm Park Dis Dement Sect (1992) 0.83
600 MHz 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances. J Pharm Biomed Anal (1993) 0.82
Dansyl chloride derivatization of methamphetamine: a method with advantages for screening and analysis of methamphetamine in urine. J Anal Toxicol (2002) 0.82
Response of the hypothalamic-pituitary-adrenal axis to lumbar puncture induced stress. J Alzheimers Dis (2000) 0.78
CSF neurotransmitter markers in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (1986) 0.78
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem (2006) 4.29
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2012) 1.70
Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res (2005) 1.64
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem (2005) 1.51
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol (2002) 1.44
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics (2006) 1.42
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiol Aging (2010) 1.35
Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J Neurosci (2004) 1.33
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage (2009) 1.29
Nitrogen fixation and hydrogen metabolism in cyanobacteria. Microbiol Mol Biol Rev (2010) 1.28
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis (2010) 1.27
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Regional network of magnetic resonance imaging gray matter volume in healthy aging. Neuroreport (2006) 1.27
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Age-related networks of regional covariance in MRI gray matter: reproducible multivariate patterns in healthy aging. Neuroimage (2009) 1.23
Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. Biol Psychiatry (2010) 1.22
Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study. Psychiatry Res (2011) 1.21
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain (2008) 1.20
Proteomic studies of diauxic lag in the differentiating prokaryote Streptomyces coelicolor reveal a regulatory network of stress-induced proteins and central metabolic enzymes. Mol Microbiol (2003) 1.20
Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am J Psychiatry (2003) 1.19
Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics (2006) 1.19
Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog Neurobiol (2011) 1.18
Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther (2009) 1.17
Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One (2012) 1.17
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. PLoS One (2011) 1.16
Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data. PLoS One (2013) 1.15
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15
Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. Chem Res Toxicol (2002) 1.15
Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener (2010) 1.15
Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol (2009) 1.12
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov (2013) 1.12
Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am (2013) 1.11
Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatr Psychiatry Neurol (2006) 1.10
Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. Neuroimage (2011) 1.10
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol (2009) 1.09
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology (2013) 1.08
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord (2009) 1.08
Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol Imaging (2008) 1.07
Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J Neurol (2006) 1.07
The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. Alzheimers Dement (2008) 1.05
Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. Cereb Cortex (2006) 1.05
Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet (2006) 1.04
Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb Chem High Throughput Screen (2005) 1.04
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn (2010) 1.03
White matter microstructure in relation to education in aging and Alzheimer's disease. J Alzheimers Dis (2009) 1.03
High-resolution capillary tube NMR. A miniaturized 5-microL high-sensitivity TXI probe for mass-limited samples, off-line LC NMR, and HT NMR. Anal Chem (2002) 1.03
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol (2003) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol (2011) 1.02
Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study. J Alzheimers Dis (2011) 1.02
Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology (2002) 1.01
Immunotherapy for Alzheimer's disease. Lancet Neurol (2003) 1.01
Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem (2005) 1.00
Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging (2006) 1.00
Cognitive intervention in Alzheimer disease. Nat Rev Neurol (2010) 0.99
Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol (2011) 0.99
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging (2012) 0.98
Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin Chem (2013) 0.98
Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PLoS One (2012) 0.98
Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnestic mild cognitive impairment. Hum Brain Mapp (2009) 0.97